ClinicalTrials.gg
CompletedNCT06964776Updated Mar 27, 2026

A Study of LY4268989 (MORF-057) in Healthy Participants

A Phase 1 interventional study of LY4268989 and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are healthy as determined by medical evaluation including medical history, physical examination, laboratory test, (ECGs), and vital signs.
  • Cohort 5 includes Japanese participants. To qualify, the participants must be first-generation Japanese in the US, defined as the participant's biological parents, and all the participant's biological grandparents, being of exclusive Japanese descent, and being born in Japan.
  • Cohort 5 includes Chinese participants. To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China.
  • Have a within the range of 18.0 to 32.0 kilogram/square meter (kg/m²), inclusive, at screening.

Exclusion criteria

Exclusion Criteria:

  • Have a current or recent acute, active infection. For at least 30 days before screening and up to Day 1, participants must have no symptoms or signs of confirmed or suspected infection, and must have completed any appropriate anti-infective treatment.
  • Have presence of significant uncontrolled respiratory, cerebrocardiovascular, cardiovascular, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or psychiatric disorders, or abnormal laboratory values at screening that, in the opinion of the sponsor or investigator, pose an unacceptable risk to the participant if participating in the study or of interfering with the interpretation of data.
  • Are to an extent that participation in the study would pose an unacceptable risk to the participant as determined by the investigator.
  • Use or intend to use prescription or nonprescription medication, including dietary supplements, vitamins, herbal supplements, traditional Chinese medicine, or alternative medicines, within 14 days or 5 half-lives (whichever is longer), prior to dosing, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    LY4268989 or Placebo Cohort 1 (Blinded)

    Participants will receive LY4268989 orally or placebo single dose followed by BID administration

    Drug: LY4268989 · Drug: Placebo

  • Experimental
    LY4268989 Cohort 2 (Open-Label)

    Participants will receive LY4268989 orally tablet (formulation compared to capsule formulation) in a fasted state

    Drug: LY4268989

  • Experimental
    LY4268989 Cohort 3 (Open-Label)

    Participants will receive multiple doses of LY4268989 orally BID administration with midazolam orally and intravenously (IV).

    Drug: LY4268989 · Drug: Midazolam

  • Experimental
    LY4268989 or Placebo Cohort 4 (Blinded)

    Participants will receive single escalating doses of LY4268989 orally or placebo

    Drug: LY4268989 · Drug: Placebo

  • Experimental
    LY4268989 Cohort 5 (Blinded)

    Participants will receive multiple doses of LY4268989 orally or placebo

    Drug: LY4268989 · Drug: Placebo

  • Experimental
    LY4268989 Cohort 6 (Open-Label)

    Participants will receive LY4268989 single dose orally in a fasted and fed state

    Drug: LY4268989

  • Experimental
    LY4268989 Cohort 7 (Open-Label)

    Participants will receive multiple doses of LY4268989 orally BID administration in a fed state

    Drug: LY4268989

  • Experimental
    LY4268989 Cohort 8 (Open-Label)

    Participants will receive multiple doses of LY4268989 orally BID administration with midazolam IV in a fasted state.

    Drug: LY4268989 · Drug: Midazolam

Interventions

  • Administered orally

  • DrugPlacebo

    Administered placebo

  • DrugMidazolam

    Administered orally

  • DrugMidazolam

    Administered intravenously (IV)

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989 (Cohort 1) and (Cohort 5)

    Time frame: Day 1 to Day 17

  2. PK: Area Under the Concentration Curve (AUC) of LY4268989 (Cohort 1) and (Cohort 5)

    Time frame: Day 1 to Day 17

  3. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Cohort 1), (Cohort 3), and (Cohort 5)

    A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module

    Time frame: Baseline to Study Completion (Up to Day 17)

  4. Number of Participants with TEAEs and SAEs (Cohort 4)

    A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module

    Time frame: Baseline to Study Completion (Up to Period 4, Day 4)

  5. PK: Cmax of LY4268989 (Cohort 2)

    Time frame: Day 1 to Day 13

  6. PK: AUC of LY4268989 (Cohort 2)

    Time frame: Day 1 to Day 13

  7. PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 3)

    PK of midazolam and 1'-hydroxymidazolam (AUC), where midazolam is administered alone and in the presence of LY4268989

    Time frame: Day 1 to Day 17

  8. PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 8)

    PK of midazolam and 1'-hydroxymidazolam (AUC), where midazolam is administered alone and in the presence of LY4268989

    Time frame: Day 3 and Day 11

  9. PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 3)

    PK of midazolam and 1'-hydroxymidazolam (Cmax), when midazolam is administered alone and in the presence of LY4268989

    Time frame: Day 1 to Day 17

  10. PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 8)

    PK of midazolam and 1'-hydroxymidazolam (Cmax), when midazolam is administered alone and in the presence of LY4268989

    Time frame: Day 3 to Day 11

  11. PK: Cmax of LY4268989 (Cohort 6)

    Time frame: Day 1 to Day 7

  12. PK: AUC of LY4268989 (Cohort 6)

    Time frame: Day 1 to Day 7

  13. PK: Cmax of LY4268989 (Cohort 7)

    Time frame: Day 1 to Day 12

  14. PK: AUC of LY4268989 (Cohort 7)

    Time frame: Day 1 to Day 12

Secondary outcomes

  1. PK: Cmax of LY4268989 (Cohort 4)

    Time frame: Day 1 to Day 4

  2. PK: AUC of LY4268989 (Cohort 4)

    Time frame: Day 1 to Day 4

  3. PK: Cmax of LY4268989 (Cohort 3)

    Time frame: Time Frame: Day 6 to Day 15

  4. PK: AUC of LY4268989 (Cohort 3)

    Time frame: Time Frame: Day 6 to Day 15

  5. PK: Cmax of LY4268989 (Cohort 8)

    Time frame: Time Frame: Day 3 and Day 10

  6. PK: AUC of LY4268989 (Cohort 8)

    Time frame: Time Frame: Day 3 and Day 10

07

Study locations

1 site
  • CenExel ACT
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Feb 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2025
First posted
May 9, 2025
StartActual
May 1, 2025
Primary completionActual
Feb 17, 2026
CompletionActual
Feb 17, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06964776
Responsible party
Sponsor
First posted
May 9, 2025
Start date
May 1, 2025
Primary completion
Feb 17, 2026
Completion
Feb 17, 2026
Last update
Mar 27, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zotemtegrast

Start the discussion